Ashfield, part of UDG Healthcare, providing commercialisation services for the pharmaceutical and healthcare industry, announced the appointment of Greg Flynn as Regional President of Ashfield Commercial and Clinical in the US and Mick O’Leary as Regional President of Ashfield Commercial and Clinical in Japan, where he will lead CMIC Ashfield.
Greg Flynn will oversee US operations of commercial, clinical, medical information, pharmacovigilance and market access. Greg is transitioning to this role from his prior position as Regional President in Japan and Representative Director of CMIC Ashfield, a joint initiative between CMIC Holdings and UDG Healthcare.
Greg Flynn said: “Through the talent of our people and Ashfield’s commitment to helping improve lives, I have seen the power of what we do in this organisation. The US business has experienced phenomenal growth in the last two years and this new role is an exciting opportunity to continue that growth.”
Mick O’Leary will take over the role as Regional President in Japan, leading the CMIC Ashfield joint venture. Mick was previously the Managing Director for Ashfield Ireland, and has over 20 years’ experience in the pharmaceutical sales industry.
Mick O’Leary said: “CMIC Ashfield is a winning proposition, combining the experience and expertise of a leading international CSO, with the local knowledge and capability of one of Japan’s leading CSOs. We will continue to excel by providing flexible, evidence-based services and I look forward to working with new clients and brand challenges in Japan.”
Julian Tompkins, Global President for Ashfield Clinical and Commercial business said: “We are delighted to have appointed these critical roles for the business. Greg’s leadership in the Japanese market has yielded remarkable growth and proven his dedication to Ashfield’s success.
"The appointment of Mick O’Leary as Regional President in Japan will continue our success story and excellent results in the second largest global pharmaceutical market. He has exactly the right expertise and drive to lead CMIC Ashfield and continue our strong progress in Japan.”
